Incidence of Post-intravitreal Anti-VEGF Endophthalmitis at Thammasat University Hospital

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20141119002

Enrollment

1167

Registered

2014-11-19

Start date

2014-07-31

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

all consecutive eyes after intravitreal injections was performed at the Thammasat University Hospital endophthalmitis&#44

Interventions

all consecutive eyes after intravitreal injections was performed at the Thammasat University Hospital

Treatment

all consecutive eyes after intravitreal injections was performed at the Thammasat University Hospita

Eligibility

Sex/Gender

All

Age

30 Years to 80 Years

Inclusion criteria

Inclusion criteria: patient with endophthalmitis secondary to therapeutic intravitreal ranibizumab and bevacizumab injections

Exclusion criteria

Exclusion criteria: unreliable medical record

Design outcomes

Primary

Measure	Time frame
endophthalmitis secondary to therapeutic intravitreal ranibizumab and bevacizumab injections retrospective percent	—

Secondary

Measure	Time frame
- - -	—

Countries

Thailand

Contacts

Public ContactNavapol Kanchanaranya

Unaffiliated

navapolk@hotmail.com0836138537

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

Incidence of Post&#45;intravitreal Anti&#45;VEGF Endophthalmitis at Thammasat University Hospital